An Eight-Week, Randomized, Double-Blind, Parallel-Group, Pilot Study to Evaluate the Efficacy and Safety of Aliskiren 300 mg in Comparison With Valsartan 320 mg in Patients With Mild to Moderate Hypertension During Exercise After a Missed Dose.

Trial Profile

An Eight-Week, Randomized, Double-Blind, Parallel-Group, Pilot Study to Evaluate the Efficacy and Safety of Aliskiren 300 mg in Comparison With Valsartan 320 mg in Patients With Mild to Moderate Hypertension During Exercise After a Missed Dose.

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Mar 2012

At a glance

  • Drugs Aliskiren; Valsartan
  • Indications Hypertension
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 20 Jun 2011 Results presented at the 21st European Meeting on Hypertension.
    • 29 Oct 2009 Actual patient number (68) added as reported by ClinicalTrials.gov.
    • 29 Oct 2009 Actual end date (October 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top